MD Anderson Events
The Immunoscore: Practical Considerations and Potential Relevance
Lecture on the Immunoscore system for immunoprofiling of cancers: (J Pathol. 2014 Jan;232(2):199-209.)
The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression-based stratification. These parameters rely on tumour-cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).
Date: 5/19/14, 9am to 10am
Time: 5/19/14, 9am to 10am
Location: Life Science Plaza Main Conf. Room (LSP9.4101-4104)
Directions: LSP Building, 9th floor. 2130 W. Holcombe Blvd. Blue Shuttle and Black Shuttle: LSP stop.
Speaker Bio: Carlo B. Bifulco, M.D. is director of Translational Molecular Pathology & Molecular Pathology and director of Pathology Informatics at the Earle A. Chiles Research Institute, Providence Portland Medical Center. Dr Bifulco did his residency in Anatomic Pathology at Yale University, and spent fellowships in Oncologic Pathology, Molecular Pathology and Hematopathology in the Memorial Sloan-Kettering Cancer Center and Yale University. Dr Bifulco is part of the international team lead by Jerome Galon, which developed the immunoscore for the classification of cancers.
Contact: Jose Alaniz - (713) 834-6029 - firstname.lastname@example.org
Carlo Bifulco flyer 5.19.14.pdf (PDF, 146 KB)
- Tumor Inflammation In Melanoma
- Oncologic Emergency Medicine Education Series
- Oncology Science and Practice Forum
- Center for Cancer Epigenetics Distinguished Lecture Series
- Division of Diagnostic Imaging DIRSS: Research Seminar Series
- Division of Diagnostic Imaging Research Seminar Series (DIRSS)
- Integrative Medicine Program Lecture Series
- John H. Blaffer Lecture Series
- 2017 Alando J. Ballantyne Distinguished Lectureship